HL7 Europe was one of 73 organizations participating in the READi project kick-off meeting held in late January in Madrid, Spain. HL7 Europe is thrilled and ready to engage with partners across 18 countries to work towards enhancing Patient Representativeness and Inclusion in Clinical Research. HL7 will participate in standards alignment and interoperability as well as communication, sustainability, and stakeholder engagement. READi Consortium press release
This six-year Innovative Health Initiative Joint Undertaking (IHI JU) project aims to enhance the representativeness of underserved (US) and underrepresented (UR) populations in clinical studies by fostering a more cohesive and integrated clinical study ecosystem.
READi will help US/UR communities overcome barriers to clinical study participation, such as lack of information or awareness, mistrust, poor communication, geographic limitations, and prejudice. This will enhance research on many diseases and conditions, improve preventative care and treatment effectiveness across diverse demographic groups, and better serve society.
"HL7 Europe is excited to participate in this important initiative that will impact and improve inclusiveness and representation of underserved and underrepresented populations in clinical research across Europe” - Catherine Chronaki, General Secretary, HL7 Europe
Work Package 1 commenced during the meeting and other work packages will soon begin their work. HL7 Europe will engage in Work Packages 2 and 9: WP 2 - Platform Architecture & Implementation of Digital Platform. Specifically, ensuring HL7® FHIR® alignment, interoperability with other standards across initiatives and WP 9 - Communication, Sustainability and Stakeholder Engagement.
For more information visit the READi website and the HL7 Europe website.
The IHI JU supports this project under grant agreement No 101166227.The JU receives support from the European Union’s Horizon Europe research and innovation program and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and Medicines and Healthcare Products Regulatory Agency and Breakthtough T1D. UKRI UK Research and Innovation also supports this project.
